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ABSTRACT
In this report a new approach is introduced that allows estimation
of insulin sensitivity (SI) from orally ingested glucose during an oral
glucose tolerance test (OGTT) or a meal glucose tolerance test (MGTT)
in normal subjects. The method hinges on the classic minimal model
of glucose kinetics that is coupled with an equation describing the rate
of appearance of glucose into the circulation after oral glucose inges-
tion. The model provides an estimate of SI in a given individual based
on simple area under the curve type of calculations. To prove the
reliability of the new approach, MGTT studies performed in 10 normal
subjects were analyzed and the SI index from the MGTT was com-
pared with the SI index obtained in the same subjects from an insulin-
modified, frequently sampled iv glucose test (FSIGT). SI from the
MGTT was 13.6 6 3.9 3 1024 dL/kgzmin/mUzmL and was strongly
correlated to the SI from the FSIGT (rs 5 0.89; P , 0.01). In conclusion,
this study shows that in normal subjects the minimal model can be
applied to a MGTT/OGTT to derive an index of insulin sensitivity that
is in good agreement with the one estimated from the FSIGT. Due to
its simplicity, this method has potential for use in population studies,
but further investigation is required to ascertain its applicability to
subjects with severe insulin resistance and impaired secretory func-
tion. (J Clin Endocrinol Metab 85: 4396–4402, 2000)
INSULIN RESISTANCE plays a pivotal role in the patho-physiology of diabetes and has been associated with
obesity, cardiovascular disease, hypertension, and cancer
(1–3). In fact, insulin resistance has been shown to be a risk
factor for several of these conditions. Although excellent
methods exist for quantitative assessment of insulin sensi-
tivity in the laboratory setting (4), accurate measurement in
studies of more than a few subjects has proven problematic.
Although fasting insulin has been used as a surrogate for
insulin resistance, it bears a nonlinear relationship to insulin
action directly measured (5) and fails when there is even
subtle b-cell failure. More direct, but complex, techniques
have employed administration by vein of insulin and/or
glucose. Given the difficulty of venous administration, it
would appear highly desirable to obtain an accurate measure
of insulin sensitivity from oral administration alone. Unfor-
tunately, such methods have not been forthcoming because
of the difficulties of estimating the appearance in the sys-
temic circulation of nutrient taken by mouth and absorbed
from the gastrointestinal tract.
Nevertheless, due to the possible importance of an oral
methodology, in this manuscript we examine the feasibility
of measuring insulin sensitivity from an oral meal. To do this,
we have coupled the classic minimal model of glucose ki-
netics (6) with a simple mathematical description of glucose
absorption from the gastrointestinal tract. To examine the
reliability of the meal-based index of insulin sensitivity,
SI(oral), this parameter was compared with the insulin sensi-
tivity index estimated from the insulin-modified frequently
sampled iv glucose test (FSIGT) (7) measured in the same
subjects.
Subjects and Methods
Subjects and experimental protocol
The data used in the current study, provided by Dr. David Owens,
are part of a published study (8) to which we refer for further details.
Briefly, 10 healthy subjects (4 men and 6 women; age, 47.7 6 2.6 yr; body
mass index, 25.9 6 1.2 kg/m2) with normal glucose tolerance received
on different occasions an insulin-modified FSIGT or a meal tolerance test
(MGTT). Both tests were performed in the morning after a 10-h overnight
fast.
The insulin-modified FSIGT consisted of a 300 mg/kg glucose bolus
at time zero, followed by an insulin injection of 0.03 U/kg at 20 min, as
previously described (7). Blood was sampled at 230, 215, 21, 1, 2, 3, 4,
5, 6, 7, 8, 10, 12, 14, 16, 19, 22, 23, 24, 25, 27, 30, 40, 50, 60, 70, 80, 90, 100,
120, 150, and 180 min.
The meal was mainly solid, with a small amount of juice and milk.
It consisted of 15 g Weetabix, 10 g skimmed milk, 250 mL pineapple juice,
50 g white meat chicken, 60 g wholemeal bread, and 10 g polyunsatu-
rated margarine. The total energy was 482 Cal; the total carbohydrate
was approximately 75 g. The meal was eaten within 10 min. Blood
samples were collected at 230, 21, 10, 20, 30, 40, 50, 60, 75, 90, 120, 150,
180, 210, and 240 min.
Analytical techniques
The plasma glucose concentration was measured by a glucose oxidase
method. Immunoreactive insulin was measured in both tests by a con-
ventional RIA method (antibody M8309 from Novo-Nordisk, Bags-
vaerd, Denmark).
Data analysis
The analysis of both the FSIGT and the MGTT studies exploits the
classic minimal model (6). Whereas during the FSIGT glucose enters the
systemic circulation directly, during the MGTT food is ingested, and
nutrients, including glucose, encounter the systemic circulation only
after absorption from the gastrointestinal tract and passage through the
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liver (see Fig. 1). Making explicit the appearance of exogenous glucose
into the minimal model yields:
g˙~t! 5 2@p1 1 x~t!#g~t! 1 p1gb 1
ra~t!
V
; g~0! 5 gb
x˙~t! 5 2p2x~t! 1 p3@i~t! 2 ib#; x~0! 5 0
(I)
where ra is the generic expression for the rate of entry of exogenous
glucose into the systemic circulation per unit BW (milligrams per kg/
min). During the FSIGT, ra coincides with the impulse injection of a
glucose dose D (milligrams per kg), i.e. ra(FSIGT) 5 Dd(t); during the
MGTT/OGTT, ra coincides with the rate of absorbed glucose, i.e.
ra(MGTT/OGTT) 5 RaABS(t), where RaABS is defined as the posthepatic
appearance of newly absorbed glucose.
Most model variables/parameters were previously described (6); g is
the plasma glucose concentration (milligrams per dL), with gb denoting
its basal value, 3 is insulin action (minutes21) exerted on glucose dis-
posal from an insulin compartment remote from plasma, i is the plasma
insulin concentration (microunits per mL), with ib denoting its basal
value, V is the glucose distribution volume per unit BW (milliliters per
kg), p2 (minutes
21) governs the speed of rise and decay of insulin action,
and p3 (minutes
22 per mU/mL) governs its size.
Insulin sensitivity from the FSIGT
The minimal model parameters p1, p2, p3, and V were estimated by
weighted nonlinear least squares from glucose and insulin data collected
during an insulin-modified FSIGT as previously described (9). As is
usual, measurements from the first 8 min after iv glucose were ignored
in model identification. The insulin sensitivity index, SI(FSIGT) (milliliters
per kg/minzmU/mL), was calculated as:
SI~FSIGT! 5
p3
p2
V 5 SIV (II)
SI(FSIGT) is thus the minimal model fractional (i.e. per unit volume) index,
SI, multiplied by the minimal model estimate of the glucose distribution
volume, V. So defined, SI(FSIGT) has the same units of the analogous
clamp index (10) and of the SI(oral) index derived as described below.
Insulin sensitivity from the MGTT
The challenge in using the minimal model to analyze oral MGTT/
OGTT data is to describe mathematically how exogenous glucose
reaches the systemic circulation. We made the assumption that the
profile of RaABS resembles an anticipated version of glucose excursion
above basal, Dg(t) 5 g(t) 2 gb. Following the principle of parsimony, we
used a simple parsimonious parametric representation for describing the
relationship between RaABS and Dg:
Dg˙~t! 5 2aDg~t! 1 bRaABS~t! (III)
where a is a parameter governing the delay and smoothness of Dg with
respect to RaABS, and b is a scale factor. Initially we assumed Dg ($0)
during the test; subsequently, we generalized the analysis by allowing
glucose to take on values below its basal level late during the test.
Substituting the expression for RaABS given by Eq III into the minimal
model equations yields
g˙~t! 5 2@p1 1 x~t!#g~t! 1 p1gb 1
@aDg~t! 1 Dg˙~t!#
bV
; g~0! 5 gb
x˙~t! 5 2p2x~t! 1 p3@i~t! 2 ib#; x~0! 5 0
(IV)
By integrating the minimal model equation describing insulin action (11,
12), the following expression for insulin sensitivity during an oral test
is obtained:
SI~oral! 5
p3
p2
V 5
E
0
‘
x~t!dt
E
0
‘
@i~t! 2 ib#dt
V (V)
Thus, what remains to be determined is the integral of x(t), the time
course of insulin action during the test. The resulting expression for
SI(oral) (milliliter per kg/minzmU/mL) is the following (see details in
Appendix):
SI~oral! 5
f z Doral
AUC@Dg~t!/g~t!#
AUC@Dg~t!#
2 GE z AUC@Dg~t!/g~t!#
AUC@Di~t!#
(VI)
where AUC denotes the area under the curve calculated from time zero
to the end of the test, GE 5 p1V is glucose effectiveness (milliliters per
kg/min), Doral is the dose of ingested glucose per unit of body weight
(milligrams per kg), and f is the fraction of ingested glucose that actually
appears in the systemic circulation (i.e. survives gastrointestinal absorp-
tion and one-pass hepatic uptake).
When the glucose concentration falls below the basal level during the
test, the equation for insulin sensitivity becomes
SI~oral!
5
f z Doral
AUC@Dg~t!/g~t!#0
t0 2 AUC@Dg~t!/g~t!#t0
‘
AUC@Dg~t!#0
t0 2 AUC@Dg~t!#t0
‘ 2 GE z AUC@Dg~t!/g~t!#
AUC@Di~t!#
(VII)
The AUC of Dg/g and Dg are separately calculated in the intervals 0-t0
and t0-‘, and the negative AUC calculated in the interval t0-‘ is sub-
tracted from the positive AUC calculated in the interval 0-t0.
Calculation of SI(oral) with Eq VI and VII requires the investigator to
insert values for GE and f. Generally, individual estimates of GE and f
are not available. Therefore, mean values derived from the literature
must be used. In the present study GE was fixed at 0.024 dL/kgzmin, i.e.
the mean value of glucose effectiveness in normal subjects reported in
the review by Best et al. (13). Estimates of f, fraction of glucose taken
orally to appear in the systemic circulation during an OGTT, vary be-
tween 70–100% (14) (see Discussion). In a previous study (15) we esti-
mated that after a mixed meal the average absorption of oral glucose was
FIG. 1. Diagram of the minimal model used to interpret the insulin-
modified FSIGT and the MGTT/OGTT. The glucose mass input to the
model, ra(t), is the impulsive dose of glucose, Dd(t), for the FSIGT, or
the rate of appearance of absorbed glucose, RaABS(t), for the MGTT/
OGTT.
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80% (n 5 7; range, 67–95%). We thus set f 5 0.8 in the formulas used to
calculate SI(oral).
It is worth noting that evaluation of SI(oral) requires that the AUCs are
calculated from the beginning of the test (time zero) until the glucose
system returns to the pretest steady state. In the present study, insulin
sensitivity values were calculated over the interval 0–240 min (see Dis-
cussion), and AUCs were computed using the trapezoidal rule.
Sensitivity analysis
Because values of glucose effectiveness, GE, and fractional splanchnic
absorption of oral glucose, f, are assumed in this method, we examined
the dependence of calculated SI(oral) upon the assumed values of GE and
f. A sensitivity analysis was performed in which we evaluated how the
estimate of SI(oral) changes in relation to a 650% change in glucose
effectiveness (assuming GE between 0.036 and 0.012 dL/kgzmin) and in
relation to a 620% change in the absorption of oral glucose (assuming
f between 0.96–0.64).
The impact of a shorter duration of the MGTT (180 instead of 240 min)
and of a reduction of the sampling frequency (one sample every 30 min)
on the estimation of SI(oral) was also evaluated by calculating SI(oral) from
the glucose and insulin data measured at 230, 21, 30, 60, 90, 120, 150,
and 180 min.
Statistical analysis
Results are given as the mean 6 sem. Due to the presence of a subject
who was very sensitive to insulin, the distributions of SI(FSIGT) and SI(oral)
were not normal. We thus used the Wilcoxon signed rank test to evaluate
differences between SI(FSIGT) and SI(oral), and Spearman’s rank correlation
coefficient (rs) to examine the strength of the association between them.
Results
Mean plasma glucose and insulin concentrations during
the insulin-modified FSIGT and during the MGTT are shown
in Fig. 2. Of note is that by the end of the MGTT at 240 min,
glucose and insulin had both virtually returned to their re-
spective pretest levels. Of course, this does not prove that all
oral glucose had been absorbed or that the metabolism of oral
glucose was complete (see Discussion).
The FSIGT-based estimate of fractional insulin sensitivity,
SI; the minimal model volume of glucose distribution, V; and
the insulin sensitivity, SI(FSIGT) 5 SI 3 V, together with the
MGTT-based estimate of insulin sensitivity, SI(oral), are listed
in Table 1 for the 10 subjects. SI(oral) was strongly correlated
with SI(FSIGT) (rs 5 0.89; P , 0.01; see Fig. 3). Despite the
strong correlative relationship between the tests, the absolute
values of SI(oral) and SI(FSIGT) were significantly different from
each other, with the value from the oral test being about twice
that from the iv test (13.6 6 3.9 vs. 6.2 6 1.3 3 1024 dL/
kgzmin/mUzmL; P , 0.01). When calculation of SI(oral) was
performed relying on a reduced sampling schedule of only
eight glucose and insulin samples collected between 0–180
min, results were virtually the same; SI(oral) was 12.9 6 3.5 3
1024 dL/kgzmin/mUzmL and remained very well correlated
with SI(FSIGT) (rs 5 0.90; P , 0.01). Of note is that accuracy was
maintained in individual subjects, as demonstrated by the
strong correlation between the two SI(oral) estimates obtained
FIG. 2. Average concentrations of glucose and insulin during the insulin-modified FSIGT and the MGTT in normal subjects (mean 6 SEM;
n 5 10).
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from the full and the reduced sampling schedule (rs 5 0.99;
P , 0.01).
The results of the sensitivity analysis indicated that in
these normal subjects calculation of SI(oral) is little influenced
by changes in the value of glucose effectiveness. A 650%
change in GE (range, 0.012–0.036 dL/kgzmin) produced only
a 62.3% change in SI(oral) (range, 13.9–13.3 3 10
24 dL/
kgzmin/mUzmL). In contrast to its little dependence upon
glucose effectiveness, in these normal subjects the value of
SI(oral) was quite sensitive to changes in f; a 620% change in
f (range, 0:96–0.64) produced a 621% change in SI(oral)
(range, 16.4–10.7 3 1024 dL/kgzmin/mUzmL).
Discussion
Overwhelming interest in insulin resistance as a risk factor
for chronic disease is reflected in the widespread application
of the minimal model methodology to large population
groups. For example, the method was applied to 1524 sub-
jects in the Insulin Resistance and Atherosclerosis Study (16),
and those tests have been repeated in a follow-up study. The
method was also used in population genetics studies such as
FUSION, in which minimal model parameters, including
insulin sensitivity, SI, are tested for linkage with markers on
the human genome (17). Obviously, complex laboratory ap-
proaches are not applicable to a proliferating number of large
studies; on the contrary, the iv injection of glucose and in-
sulin is a challenge that entails cost and labor, and it would
be useful if they could be avoided.
It would be beneficial if the simpler oral route of glucose
administration could be the basis upon which SI were cal-
culated. In the present work we have developed the theo-
retical framework for such a methodology. This approach
was originally rejected because of the need to estimate the
rate of entry of orally taken glucose into the systemic circu-
lation. However, at that time we were most concerned with
studies using small numbers of subjects in which iv admin-
istration was feasible and not prohibitively costly. However,
the accelerating rate of appearance of large studies encour-
aged us to reexamine this methodology.
In the present study we introduce a new approach that
exploits the minimal model, but adds a parsimonious para-
metric representation of splanchnic glucose absorption that
allows the measurement of insulin sensitivity in each indi-
vidual from an AUC type of calculation. Obviously such a
calculation is simpler to perform than the nonlinear estima-
tion procedure required for the iv method (6, 18).
We have examined this new approach to derive estimates
of insulin sensitivity from meal glucose tolerance data in 10
subjects with normal glucose tolerance. Comparing the SI
index obtained with this approach with the insulin-modified
iv test by correlation analysis revealed a strong and highly
significant correlation between the SI index measured in the
two experiments (rs 5 0.89; P , 0.01). This result suggests
that both methods are measuring similar physiological phe-
nomena, most likely the sum effects of insulin to enhance
glucose uptake by peripheral tissues (mostly muscle) and
concomitantly suppress liver glucose output. The present
results are reminiscent of the linear relationship between
results from the minimal model and the euglycemic glucose
clamp method (10). Thus, it can be argued that the meal
tolerance test (and presumably the oral glucose tolerance
test) can be used, along with Eq VI and VII above, to yield an
acceptable index of insulin sensitivity in normal individuals.
One striking result from the present study is that although
one might predict a one to one concordance between the
FSIGT and MGTT estimates of SI because they both rely on
TABLE 1. Intravenous- and oral-based estimates of insulin sensitivity
Subject no. S1 (1024 min/mUzmL) V (dL/kg) S1(FSIGT) (1024 dL/kgzmin/mUzmL) S1(oral) (1024 dL/kgzmin/mUzmL)
1 3.3 1.7 5.5 7.6
2 3.2 1.4 4.5 13.3
3 3.5 1.5 5.0 9.0
4 10.9 1.4 15.8 46.8
5 1.5 1.2 1.8 4.2
6 3.2 1.3 4.0 6.6
7 4.2 1.5 6.1 17.8
8 2.0 1.2 2.3 6.8
9 8.7 1.3 11.4 13.7
10 4.5 1.3 5.8 9.6
Mean 6 SEM 4.5 6 0.9 1.4 6 0.1 6.2 6 1.34 13.6a 6 3.9
a P , 0.01 vs. S1(FSIGT), by Wilcoxon signed rank test.
FIG. 3. The relation between SI(oral) and SI(FSIGT) in 10 normal sub-
jects. The degree of association between SI(oral) and SI(FSIGT) was
assessed using the nonparametric Spearman’s method due to the
presence of a subject (no. 4 in Table 1) whose insulin sensitivity was
much higher than the others. When the correlation analysis was
repeated without this subject, Pearson’s r was 0.63 (P 5 0.068).
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the minimal model and have the same units, we found that
SI(oral) was numerically twice as great as SI(FSIGT) (13.6 vs.
6.2 3 1024 dL/kgzmin/mUzmL). Several explanations for this
unexpected result may be suggested. One possibility is that
the way RaABS is depicted in the model is not sufficiently
accurate. To allow derivation of SI from MGTT/OGTT data,
we resorted to a simple parametric description based on the
idea that RaABS is an anticipated version of glucose excursion
above basal. The question of whether this description is too
simplistic needs to be addressed by future studies in which
the time course of RaABS will be accurately assessed with the
appropriate modeling and experimental techniques (such as
the specific activity clamp). However, we speculate that the
high degree of association between SI(FSIGT) and SI(oral) makes
it unlikely that the description of RaABS is affected by gross
errors. Another possibility is related to the fact that with this
method one is forced to estimate the fraction of glucose taken
by mouth that appears in the vena cava, emanating from the
liver. There are several reasons why f, which was assigned
a value of 0.8, may have been overestimated in this study.
First, we assumed that gastrointestinal absorption of glucose
is finished by 240 min. This was done for convenience, be-
cause the database used herein included a 240-min meal
tolerance test. However, in a mixed meal tolerance test, ab-
sorption of nutrients is much slower than with a carbohy-
drate meal. Certain peptide hormones, such as glucagon-like
peptide-1 (GLP-1), act as brakes on motility and may well
slow the movement of ingested carbohydrate down the gas-
trointestinal tract. We can expect that this phenomenon
would be less of a problem with an OGTT, because the
so-called brake peptides are released with intake of fat. How-
ever, the value of 0.8 for f is not without foundation. In a
previous MGTT study (15) in which f was estimated, par-
ticular care was employed in terms of frequency of blood
sampling, duration of the experiment, and modeling anal-
ysis. Of course, we cannot exclude that in the present MGTT
study f was lower than 0.8 (in the literature there are studies
reporting values of f as low as 0.7 for the OGTT). Thus,
further careful examination of fractional absorption of orally
administered glucose is justified to determine the external
value of f that should be used with the present new meth-
odology. An additional caveat is that there may well be
differences in f for different states, particularly in patients
with diabetes, in whom neuropathy may alter gastrointes-
tinal function.
Despite these considerations, it is possible that the out-
come of SI(oral) . SI(FSIGT) is not due solely to an overestima-
tion of f. In fact, as shown by the sensitivity analysis, even
with f reduced to 0.64, SI(oral) is reduced only to 10.7 3 10
24
dL/kgzmin/mUzmL, still higher than SI(FSIGT). In this regard
it is important to remember that the minimal model is based
upon a single compartment simplification of glucose distri-
bution. It has been shown that this simplification causes
difficulties in accounting for the rapid changes in glucose
concentration experienced after an iv glucose injection (11,
12, 19). In contrast, it is likely that when glucose and insulin
change more slowly, such as during a MGTT or an OGTT, a
single compartment representation is sufficiently adequate
(20). Whether the single compartment simplification may
differently affect the calculation of SI from the iv vs. the oral
test requires further examination.
Another possible explanation for the finding of SI(oral) .
SI(FSIGT) is related to the different routes of glucose and
insulin appearance during the meal and the FSIGT. During
the meal, both glucose and insulin reach the peripheral
circulation after passing through the portal vein. In con-
trast, during the insulin-modified FSIGT, glucose is in-
jected iv, and the insulin concentration is the result of a mix
of endogenously secreted insulin and exogenously admin-
istered insulin, the latter component being predominant
after insulin injection at 20 min. The possibility that
SI(FSIGT) is influenced by the use of peripheral, rather than
portal, insulin delivery appears unlikely in view of the
recent evidence from Steil et al. (21). These investigators
demonstrated directly, by portal vs. peripheral infusion,
that during the FSIGT portal insulin delivery per se does
not significantly affect insulin’s ability to inhibit hepatic
glucose release after an iv glucose challenge. Thus, it does
not seem likely that in the present study SI(FSIGT) was
underestimated with respect to SI(oral) due to the use of
peripherally administered exogenous insulin during the
FSIGT. A far as the different route of glucose administra-
tion is concerned, Cherrington and co-workers (22) have
reported evidence suggesting that when glucose enters the
systemic circulation through the portal vein, a neurally
mediated portal signal is triggered that enhances glucose
uptake by the liver. However, as this portal signal appears
to inhibit nonhepatic glucose uptake by an amount iden-
tical to the amount it increases hepatic glucose uptake, the
insulin sensitivity of glucose-consuming tissues should
not be affected. Whether such a portal signal is also able
to enhance the inhibitory effect of insulin on hepatic glu-
cose production (which would augment the overall insulin
sensitivity) is still unknown.
Another factor that could contribute to augment SI(oral)
with respect to SI(FSIGT) is GLP-1. Specifically, while GLP-1 is
a known insulin secretagogue, there is some evidence that
this peptide may stimulate insulin-independent glucose dis-
posal in peripheral tissues (23). Alternatively, there may be
other gastrointestinal factors enhancing insulin sensitivity at
the liver or muscle that remain to be identified.
Another factor that may play some role is glucagon. It
is worth emphasizing that the effects of glucagon on glu-
cose metabolism are not explicitly described by the min-
imal model. In fact, the model interprets glucose and in-
sulin data, during both the meal and the FSIGT, as the
result of the effects of only two factors: glucose effective-
ness and insulin sensitivity. Thus, it is possible that the
different patterns of glucagon secretion during the FSIGT
and the meal may alter the calculation of SI. The glucagon
concentration is inhibited in either the FSIGT or meal
protocol. There are, however, contrasts in the patterns by
which glucagon returns to its basal level. During a meal,
glucagon begins a slow resumption to the basal level after
approximately 90 min (24). In contrast, during the insulin-
modified FSIGT, glucagon shows a rapid and marked in-
crease after 30 min that counteracts the glucose-lowering
effect achieved by means of the exogenous insulin injec-
tion (21). An increasing glucagon has two concomitant and
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opposite effects on hepatic glucose production: it stimu-
lates hepatic glucose production and potentiates insulin
inhibitory effect on hepatic glucose production. The net
effect observed by Steil et al. was a quick resumption of
hepatic glucose production from nearly complete suppres-
sion back to basal [in humans, as shown by Vicini et al. (25),
hepatic glucose production also exhibits a marked over-
shoot over the baseline]. It can be speculated that this
behavior of hepatic glucose production, occurring in con-
comitance with a still elevated insulin profile, is likely to
be interpreted by the minimal model as the inability of
insulin to maintain the inhibition of hepatic glucose pro-
duction. This might lead to an underestimation of insulin
sensitivity during the insulin-modified FSIGT, and thus
contribute to reduce SI(FSIGT) with respect to SI(oral).
Glucose uptake is dependent upon insulin-independent
as well as insulin-dependent mechanisms. In the present
oral-based method the insulin-independent component,
glucose effectiveness, was assumed. Fortunately, how-
ever, the resulting insulin sensitivity value was virtually
independent of the estimate of glucose effectiveness. A
650% change in glucose effectiveness produces only a
62.3% change in the estimate of SI(oral). Thus, at least in
normal subjects, the MGTT/OGTT estimate of SI does not
seem to depend on the assumed value for glucose effec-
tiveness. However, the relative importance of glucose ef-
fectiveness to overall glucose tolerance increases substan-
tially in subjects with impaired glucose tolerance as well
as those with type 2 diabetes. Thus, the relative unimpor-
tance of the estimate of effectiveness to the insulin sensi-
tivity value requires additional examination in different
groups of volunteers.
Clearly, calculating insulin sensitivity from an oral test is
appealing. Insulin sensitivity derived from MGTT/OGTT
data appears to require only eight glucose/insulin samples
between 0 and 180 min. In fact, the mean value of SI(oral) and
its degree of correlation with SI(FSIGT) did not change when
only eight samples (two basal samples and one sample every
30 min until 180 min) were used in AUC calculations.
In conclusion, a new approach for the estimation of
insulin sensitivity from a meal tolerance test has been
presented that exploits the minimal model approach. The
SI index obtained with this approach in normal subjects
appears to be closely associated to the one estimated from
insulin-modified FSIGT data. Therefore, our results indi-
cate that the minimal model applied to the analysis of
MGTT/OGTT data is potentially useful to measure insulin
sensitivity when use of the insulin-modified FSIGT is not
feasible for economic or practical reasons. The present
study in normal humans is the first attempt and an obvious
prerequisite. Further work is needed to define the domain
of validity of this method throughout the whole range of
insulin sensitivity and assess its applicability to patients
with diabetes mellitus. If validated in disease states, the
new test may be preferable to the FSIGT in large studies
because of its simplicity.
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Appendix
The purpose here is to show how insulin sensitivity can be cal-
culated from MGTT/OGTT data. Making reference to Fig. 1, we
denote with RaABS(t) (mgkg
21min21) the rate of appearance of the
ingested glucose into the systemic circulation during a MGTT/OGTT.
To give RaABS(t) a parsimonious representation, we make the as-
sumption that its profile resembles an anticipated version of the
glucose excursion above basal, Dg(t)5g(t)-gb. The simplest functional
relationship between RaABS and Dg accounting for this idea is the
following:
Dg˙(t) 5 2aDg~t) 1 bRaABS(t) (A1)
where a is a parameter governing the degree of delay and smoothness
of Dg with respect to RaABS and b is a scale factor. RaABS can thus be
written as follows:
RaABS(t) 5
@aDg(t) 1 Dg˙(t)]
b
(AII)
For the sake of simplicity, we assume that Dg is always nonnegative
during the test. We will deal after with the more general case in which
glucose concentration displays an undershoot below its basal level in the
final part of the test.
Substituting the expression for RaABS(t) given by Eq AII into the
minimal model equations yield:
g˙(t) 5 2[p1 1 x(t)]g(t) 1 p1gb 1
@aDg(t) 1 Dg˙(t)]
bV
; g(0) 5 gb (AIII)
x˙(t) 5 2p2x(t) 1 p3[i(t) 2 ib]; x(0) 5 0
Integrating the equation describing insulin action dynamics (second
differential equation in Eq AIII), one obtains the following expression for
SI(oral):
SI(oral) 5
p3
p2
V 5
E
0
‘
x(t)dt
E
0
‘
[i(t) 2 ib]dt
V (AIV)
The integral at the denominator is simply the area under the curve of the
measured incremental insulin concentration; the integral at the numer-
ator can be evaluated by integrating the equation describing glucose
dynamics (first differential equation in Eq. AII):
E
0
‘
x(t)dt 5 S abV 2 p1D E
0
‘
Dg(t)
g(t)
dt 1 S 1bV 2 1DE
0
‘
Dg˙(t)
g(t)
dt (AV)
It is easy to show that the second integral in the right member of Eq AV
is zero. In fact, assuming that the end of the perturbation the glucose
system returns at the pretest steady state we have:
E
0
‘
Dg˙(t)
g(t)
dt 5E
0
‘
g˙(t)
g(t)
dt 5E
0
‘
d
dt
@ln g(t)]dt 5 ln g(‘) 2 ln g(0) 5 0 (AVI)
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Substituting Eq AV for Eq AIV and taking into account the result of Eq
AVI we obtain:
SI(oral) 5
Sab 2 p1VD E
0
‘
Dg(t)
g(t)
dt
E
0
‘
Di(t)dt
(AVII)
where p1 V measures glucose effectiveness (dlkg
21 min21). The ratio a/b
is proportional to the amount of glucose that is absorbed during the test.
In fact, by integrating Eq All from 0 to infinity we have:
a
b
5
E
0
‘
RaABS (t)dt
E
0
‘
Dg(t)dt
5
f z Doral
E
0
‘
Dg(t)dt
(AVIII)
where the intergal of RaABS is the amount of glucose that has been absorbed.
This amount can be conveniently expressed as a fraction, f, of the amount
of glucose that has been ingested, Doral. By substituting Eq AVIII into Eq
AVII, using the position GE 5 p1 V, and denoting, for the sake of simplicity,
the intergal from 0 to infinity with the symbol AUC (area under the curve),
we have the following expression for insulin sensitivity:
SI(oral) 5
f z Doral
AUC@Dg(t)/g(t)]
AUC[Dg(t)]
2 GE z AUC[Dg(t)/g(t)]
AUC[Di(t)]
(AIX)
Let us now consider the more general case in which glucose exhibits
an excursion below the pretest basal level and let us denote with t0 the
time when glucose concentration crosses the baseline level and begins
its undershoot (note that t0 can be evaluated in each individual by
linearly interpolating the glucose samples that immediately precede and
follow the crossing of the baseline glucose level). In this case, the use of
Eq AII to describe RaABS throughout the experiment would imply that
RaABS becomes negative from some time before t0 (RaABS is an antici-
pated version of Dg) until the end of the experiment. To cope with such
inadequacy of Eq AII (but retaining at the same time the simplicity and
usefulness of its description of RaABS) we split the description of RaABS
by distinguishing the intervals that precede and follow t0:
RaABS(t) 5 5
@aDg(t) 1 Dg˙(t)]
b
for t,t0
2
@aDg(t) 1 Dg˙(t)]
b
for t $ t0
(AX)
According to Eq AX, RaABS has an abrupt change of sign in t0. In this way
we limit to a minimum the interval where RaABS becomes negative and
keeps on using a parametric description of RaABS that allows derivation of
a simple formula for insulin sensitivity. In fact, using the same rationale
outlined above we obtain the following expression for S(oral):
SI(oral)
5
f z Doral
AUC[Dg(t)/g(t)]0
t0 2 AUC[Dg(t)/g(t)] to
‘
AUC[Dg(t)]0
t0 2 AUC[Dg(t)] t0
‘ 2 GE z AUC[Dg(t)/g(t)]
AUC[Di(t)]
(AXI)
The only differnce with respect Eq AIX lies in the fraction multiplying
fzDoral: the AUCs of Ag/g and Dg are separately calculated in the in-
tervals 0-t0 and to- and the negative AUC calculated in the interval t0-‘
is subtracted from the positive AUC calculated in the interval 0-t0.
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